PTGS2 and depressive symptom measurement: Taken together, the results of these behavioral assays of depression, demonstrating that the selective inhibitor of COX-2, celecoxib, ameliorates responses associated with depression, suggest that at least part of the induction of depression phenotypes is due to COX-2 participation.